Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $1.0 million.

  • Seres Therapeutics' Depreciation & Amortization (CF) fell 2564.1% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 2911.06%. This contributed to the annual value of $5.5 million for FY2024, which is 1241.39% down from last year.
  • Latest data reveals that Seres Therapeutics reported Depreciation & Amortization (CF) of $1.0 million as of Q3 2025, which was down 2564.1% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Depreciation & Amortization (CF) peaked at $1.7 million during Q3 2022, and registered a low of $1.0 million during Q3 2025.
  • Over the past 5 years, Seres Therapeutics' median Depreciation & Amortization (CF) value was $1.5 million (recorded in 2021), while the average stood at $1.4 million.
  • As far as peak fluctuations go, Seres Therapeutics' Depreciation & Amortization (CF) skyrocketed by 1816.27% in 2022, and later tumbled by 3351.72% in 2024.
  • Quarter analysis of 5 years shows Seres Therapeutics' Depreciation & Amortization (CF) stood at $1.6 million in 2021, then increased by 4.83% to $1.6 million in 2022, then grew by 0.31% to $1.6 million in 2023, then tumbled by 33.52% to $1.1 million in 2024, then decreased by 3.78% to $1.0 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $1.0 million for Q3 2025, versus $1.1 million for Q2 2025 and $1.1 million for Q1 2025.